Otros idiomas Orgenesis Inc.

Acciones

ORGS

US68619K2042

Mercado cerrado - Nasdaq Otros sitios de cotización 22:30:01 03/05/2024			Varia. Cinco días.	Varia. 1 de enero.
0,527 ^USD	-2,95 %		+3,92 %	+5,25 %

15/04	Orgenesis Inc. informa de los resultados del ejercicio cerrado el 31 de diciembre de 2023	CI
10/04	Germfree y Orgenesis Inc. anuncian la compra de activos y una asociación estratégica destinada a revolucionar la terapia celular y génica mediante la producción descentralizada y la accesibilidad mundial	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

North American Morning Briefing : Powell Comments, -2-	16/04
Orgenesis Provides Year End Business Update	15/04
Orgenesis Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	15/04
Orgenesis : Non-Reliance on Previously Issued Financial Report - Form 8-K	15/04
Germfree and Orgenesis Announce Asset Purchase and Strategic Partnership Intended to Revolutionize Cell and Gene Therapy Through Decentralized Production and Global Accessibility	10/04
Germfree and Orgenesis Inc. Announce Asset Purchase and Strategic Partnership Intended to Revolutionize Cell and Gene Therapy Through Decentralized Production and Global Accessibility	10/04
North American Morning Briefing : Stocks Seen -2-	02/04
North American Morning Briefing : Markets Steady -2-	26/03
North American Morning Briefing : Stock Futures -2-	19/03
Vered Caplan, CEO of Orgenesis, to Present at the Bioprocessing Summit Europe Conference	18/03
Orgenesis Consortium Awarded €1.5M EUR Grant from the Walloon Government in Belgium for EXOFASTTRACK Project Dedicated to Accelerated Development of Multiple Therapeutic Exosomes	13/03
Orgenesis Inc. announced that it has received $2.340901 million in funding	05/03
Orgenesis Inc. Announces $2.3 Million Private Placement	04/03
Orgenesis Inc. announced that it expects to receive $2.340901 million in funding	03/03
Orgenesis Consortium Awarded €2.0M EUR Grant from Walloon Government in Belgium for MAIDAM AI Project for Monitoring Decentralized ATMP Manufacturing	29/02
Orgenesis Acquires Control of Octomera with the Goal of Progressing its Decentralized Immuno-Oncology Portfolio to Clinic	31/01
Orgenesis Inc. agreed to acquire 25% stake in Octomera LLC from MM OS Holdings, L.P.	31/01
Orgenesis Inc. entered into a binding Term Sheet agreement to acquire Octomera LLC from MM OS Holdings, L.P.	24/01
Alimera Sciences Appoints New CFO	02/01
Orgenesis Ranked No. 171st Fastest-Growing Company in North America on the 2023 Deloitte Technology Fast 500 TM	14/11

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Orgenesis Inc.

Acciones

ORGS

US68619K2042

Otros idiomas

Filtros